This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts See a 44.47% Upside in Omnicell (OMCL): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Omnicell (OMCL) points to a 44.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Omnicell (OMCL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of +45.16% and +4.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?
by Zacks Equity Research
Hims & Hers benefits from strong product demand and subscriber growth ahead of second-quarter 2025 earnings, fueled by weight loss and specialty care uptake.
OMCL vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
OMCL vs. DOCS: Which Stock Is the Better Value Option?
Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
American Well (AMWL) Soars 5.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
American Well (AMWL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?
by Indrajit Bandyopadhyay
OptimizeRx bets on EHR-linked messaging and geo-targeting to stand out, but scaling in a crowded digital health field remains key.
Do Options Traders Know Something About Omnicell Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to OMCL stock based on the movements in the options market lately.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
by Zacks Equity Research
OMCL stays on investors' radar due to its strong 2025 growth targets with automation and tech services, but faces margin risks from macro and competitive headwinds.
Omnicell (OMCL) Up 27% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell's New Perioperative Clinic Setting Products May Boost Stock
by Zacks Equity Research
OMCL unveils new offerings for the perioperative and clinic setting.
Omnicell Q1 Earnings & Revenues Beat, '25 EPS View Down, Stock Up
by Zacks Equity Research
OMCL posts better-than-expected top and bottom-line results for the first quarter of 2025.
Omnicell (OMCL) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 62.50% and 4.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive HIMS Stock Before Q1 Earnings?
by Debanjana Dey
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the first quarter of 2025.
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
by Zacks Equity Research
OMCL stays on investors' radar due to the strong performance of the SaaS and Expert Services portfolio.
Here's Why Omnicell (OMCL) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
New Product Launches Benefit GMED Stock Amid Macro Issues
by Zacks Equity Research
Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
Omnicell Gains 41.6% in a Year: What's Driving the Stock?
by Zacks Equity Research
OMCL's shares rise on the back of its XT Amplify program gaining market acceptance with its offerings. However, the unfavorable macroeconomic scenario is concerning.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
by Zacks Equity Research
OMCL stays on investors' radar due to its impressive long-term growth initiative.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Omnicell (OMCL) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Omnicell (OMCL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs
by Zacks Equity Research
Illumina Collaborates with Broad Clinical Labs to set the standard for scalable single-cell research and accelerate discovery in areas such as disease modeling and drug development.